About Evogene Ltd
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Application segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and multi drug resistant organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd., a subsidiary of Tikun Olam-Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. Address: 13 Gad Feinstein Street, Rehovot, Israel, 7612002
Evogene Ltd News and around…
Latest news about Evogene Ltd (EVGN) common stock and company :
ICL (NYSE: ICL) (TASE: ICL), a leading global specialty minerals company, and Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, announced today a multi-year, strategic, collaboration agreement between ICL and Lavie Bio Ltd., a subsidiary of Evogene.
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announced today that it will release its financial results for the second quarter of 2022 on Wednesday, August 31, 2022.
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced that Professor Gal Markel, Director of the Davidoff Cancer Center & Deputy Director General of the Rabin Medical Center at Clalit Health Services in Israel, is joining Biomica's Scientific Advisory Board.
Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced that the first patient was dosed in its Phase I clinical trial that is designed primarily to evaluate the safety and tolerability of Biomica's microbiome-based immuno-oncology drug candidate, BMC128, in combination with immune checkpoint inhibitor (ICI) immunotherapy, in patients with either non-small cell lung
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares climbed 264% to close at $18.20 on Thursday. The company offered ...
Gainers Virax Biolabs Group Limited (NASDAQ: VRAX) shares jumped 364.3% to $23.22. The company offered shares at an expected ...
Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced the successful enrollment of the first patient in its first Proof-of-Concept (POC) Phase I clinical trial.
Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be presenting at Microbiome Connect Europe taking place between July 6-7, 2022, in Amsterdam, Netherlands.
Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be presenting as part of a panel at the opening session of the 7th Microbiome Movement Drug Development Summit taking place between June 21-24, 2022 in Boston, MA.
Evogene Ltd. (NASDAQ: EVGN) (TASE:EVGN) released its financial results for the first quarter ended March 31, 2022, revealing revenue of ...
Evogene (EVGN) delivered earnings and revenue surprises of -42.86% and 46.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the first quarter ended March 31, 2022.
Companies Reporting Before The Bell • American Woodmark (NASDAQ:AMWD) is likely to report quarterly earnings at $1.34 ...
Evogene (NASDAQ:EVGN) is set to give its latest quarterly earnings report on Thursday, 2022-05-26. Here's what investors need to know ...
Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be presenting at the 2022 ASCO Annual Meeting, a conference taking place in Chicago, IL from June 3 to 7, 2022.
Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be presenting at the Digestive Disease Week (DDW 2022) Conference taking place May 21-24, 2022, in San Diego, California.
Lavie Bio Ltd., a subsidiary of Evogene Ltd., (NASDAQ: EVGN) (TASE: EVGN) and a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, announced today that for the 2022 growing season currently underway, Lavie Bio successfully produced and fully sold its planned production quota to U.S. customers for result™, Lavie Bio's recently released bio-inoculant product for Spring Wheat.
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development across several market segments, announces today that it will release its financial results for the first quarter of 2022 on Thursday, May 26, 2022. Dr. Elran Haber, Chief Executive Officer of Evogene's subsidiary, Biomica Ltd., will be joining the conference call to discuss Biomica's recent activity.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rise and shine! We're gearing up for another busy day of trading with a breakdown of the biggest pre-market stock movers for Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) rose 31.9% to $3.35 in pre-market trading after jumping around 25% on ...
EverGen Infrastructure Corp. Announces Dates for 2021 Fourth Quarter and Year End Financial Results & Corporate Update Conference Call
Biomica Ltd. (Biomica), an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), reported today that it signed a collaboration agreement with the Sheba Medical Center (Sheba) in Tel Aviv, Israel, a hospital ranked by Newsweek magazine as one of the top 10 globally of 2022[1].
Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will be attending the Jefferies Virtual Synthetic Biology Week which is taking place between March 21-25, 2022.
Evogene (EVGN) delivered earnings and revenue surprises of 10% and 107.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) announced its financial results for the fourth quarter and full year of 2021, ended December ...
Evogene (NASDAQ:EVGN) reported its Q4 earnings results on Thursday, March 10, 2022 at 07:00 AM. Here's what investors ...
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the fourth quarter and full year of 2021, ended December 31, 2021.
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share ...
Evogene (NASDAQ:EVGN) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know ...
Evogene Ltd (EVGN) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
